Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCARLET study of sotorasib plus carboplatin-pemetrexed in chemotherapy-naive KRAS G12C-mutated non-squamous non-small cell lung cancer
jRCT2051210086Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Oct 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sotorasib, carboplatin and pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Amgen. Primary endpoint: Overall response by independent review. Started Oct 2021; status: active, not recruiting.
02
Drugs
sotorasibcarboplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051210086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210086.